An overview of Pexion and why it is authorised in the EU
Pexion is a veterinary medicine used in dogs to:
- reduce the frequency of generalised seizures (fits affecting most or all of the brain) due to epilepsy of unknown causes (idiopathic). It should be used after careful evaluation of alternative treatment options;
- reduce anxiety and fear associated with noise phobia.
Pexion contains the active substance imepitoin
Pexion : EPAR - Summary for the public (PDF/85.38 KB)
First published: 26/03/2013
Last updated: 15/08/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
Boehringer Ingelheim Vetmedica GmbH
|Date of issue of marketing authorisation valid throughout the European Union||
Binger Strasse 73
05/07/2018 Pexion - EMEA/V/C/002543 - II/0011/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
For the reduction of the frequency of generalised seizures due to idiopathic epilepsy in dogs for use after careful evaluation of alternative treatment options.
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 16-17 February 202119/02/2021